comparemela.com

Latest Breaking News On - Completed patient enrollment - Page 1 : comparemela.com

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum

-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23- -Strong PADCEV® Growth Driven By Combination First-Line.

United statesDisitamab vedotinDavid epsteinRoger danseyAmerican association for cancer researchSeagen incGerman hodgkin study groupCompany annual report on formDevelopment rd expensesExchange commissionAmerican society of clinical oncologyInternational conference on malignant lymphomaAmerican society of hematologyChief executive officerChief medical officerFirst line treatment

NeuroSense CEO Provides Q2 2023 Update

NeuroSense CEO Provides Q2 2023 Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomNeurosense therapeutics ltdExchange commissionPrnewswire neurosense therapeutics ltdSense therapeuticsAmyotrophic lateral sclerosisCompleted patient enrollmentScientific agreementTrial underBiomarker study completedNeurosense therapeuticAnnual reportNeurosense therapeutics

Oxurion NV: Oxurion Provides Update on Clinical Pipeline Progress

Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects US IRB Approval of Protocol Amendment

United statesRegion flamandeTom graneyMichael dillenArshadm khananiSylvie berrebi frazer hallChristopher brinzeyCompany annualClinical research at sierra eye associatesCompleted patient enrollmentDiabetic macular edemaProtocol amendmentEuronext brusselsPatient enrollmentAge related macular degenerationRetinal vein occlusion

Oxurion Provides Update on Clinical Pipeline Progress

Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve.

United statesRegion flamandeTom graneyArshadm khananiClinical research at sierra eye associatesCompleted patient enrollmentDiabetic macular edemaProtocol amendmentEuronext brusselsAge related macular degenerationRetinal vein occlusionChief executive officerReceived approvalReview boardBest corrected visionClinical research

vimarsana © 2020. All Rights Reserved.